Live Breaking News & Updates on Vbi Vaccines|Page 6

Stay updated with breaking news from Vbi vaccines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Head to Head Analysis: Advent Technologies (NASDAQ:ADN) & Environmental Tectonics (OTCMKTS:ETCC)

VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.27 and traded as low as $2.81. VBI Vaccines shares last traded at $2.91, with a volume of 95,029 shares traded. Wall Street Analysts Forecast Growth Separately, StockNews.com […] ....

Vaccines Inc , Perceptive Advisors Llc , Vaccines Company Profile , Vbi Vaccines Inc , Securities Exchange Commission , Frontier Wealth Management , Renaissance Technologies , Millennium Management , Get Rating , Exchange Commission , Street Corp , Financial Advisors , Wealth Management , Vbi Vaccines , Nasdaq Vbiv ,

VBI Vaccines (NASDAQ:VBIV) Share Price Crosses Below 200 Day Moving Average of $9.27

Shares of VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.27 and traded as low as $2.81. VBI Vaccines shares last traded at $2.91, with a volume of 95,029 shares traded. Analysts Set New Price Targets Separately, […] ....

Managers Group , Charles Schwab Investment Management Inc , Vaccines Company Profile , Vaccines Inc , Voya Investment Management , Perceptive Advisors Llc , Sg Americas Securities , Get Rating , Investment Management , Street Group , Charles Schwab Investment Management , Schwab Investment Management , Vbi Vaccines , Nasdaq Vbiv ,

VBI Vaccines (NASDAQ:VBIV) Given New $6.00 Price Target at Raymond James

VBI Vaccines (NASDAQ:VBIV – Get Rating) had its price target lowered by Raymond James from $60.00 to $6.00 in a report issued on Thursday, The Fly reports. VBI Vaccines Stock Up 8.1 % Shares of NASDAQ:VBIV opened at $3.20 on Thursday. VBI Vaccines has a 1 year low of $2.86 and a 1 year high […] ....

United Kingdom , Raymond James , Cambridge Investment Research Advisors Inc , Vaccines Inc , Millennium Management , Goldman Sachs Group Inc , Charles Schwab Investment Management Inc , Perceptive Advisors Llc , Securities Exchange Commission , Get Rating , Exchange Commission , Street Corp , Investment Research Advisors , Schwab Investment Management , Goldman Sachs Group , Sachs Group , Vbi Vaccines , Nasdaq Vbiv , Lower Price Target ,

VBI Vaccines (NASDAQ:VBIV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV – Get Rating) in a research note released on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, Raymond James dropped their price objective on shares of VBI Vaccines from $60.00 to $6.00 in a report on Thursday. VBI Vaccines Stock […] ....

United Kingdom , Raymond James , Cambridge Investment Research Advisors Inc , Vaccines Inc , Charles Schwab Investment Management Inc , Perceptive Advisors Llc , Millennium Management , Goldman Sachs Group Inc , Get Rating , Street Corp , Investment Research Advisors , Schwab Investment Management , Goldman Sachs Group , Sachs Group , Vbi Vaccines , Nasdaq Vbiv , Initiated Coverage , Stocknews Com ,

VBI Vaccines Inc. (NASDAQ:VBIV) Short Interest Down 96.5% in March

VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) was the recipient of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 532,200 shares, a drop of 96.5% from the March 15th total of 15,050,000 shares. Based on an average daily volume of 54,900 shares, the […] ....

United Kingdom , Raymond James , Perceptive Advisors Llc , Charles Schwab Investment Management Inc , Millennium Management , Vaccines Inc , Cambridge Investment Research Advisors Inc , Goldman Sachs Group Inc , Vbi Vaccines Inc , Get Rating , Street Corp , Investment Research Advisors , Schwab Investment Management , Goldman Sachs Group , Sachs Group , Vbi Vaccines , Nasdaq Vbiv ,